Spruce Biosciences
Latest round
- Series B
Last raised
- Feb 2020
Total raised
- $108M
Investors
- 9
About Spruce Biosciences
Spruce Biosciences, Inc. is a US-based biopharmaceutical company dedicated to developing therapies for rare neurological disorders, focusing on enzyme replacement therapy for conditions like Mucopolysaccharidosis Type IIIB (MPS IIIB). Established in 2016 and headquartered in San Francisco, US, Spruce Biosciences, Inc. focuses on enzyme replacement therapies. The company is headed by its CEO Javier Szwarcberg serving as of 2026. In January 2026, Spruce Biosciences, Inc. Spruce Biosciences specializes in developing innovative therapies aimed at treating rare neurological disorders, with a focus on enzyme replacement therapy. Their lead product, Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT), targets Mucopolysaccharidosis Type IIIB (MPS IIIB), addressing the underlying biochemical deficiency that leads to the progression of the disease. The company primarily serves the patients and families affected by MPS IIIB and related conditions, marketing its products in North America and Europe, which have a recognized demand for specialized treatments for rare diseases. The revenue is generated primarily through the commercialization of TA-ERT, with a business model that involves partnerships with healthcare providers and institutions, facilitating patient access to its therapies. The pricing model for TA-ERT aligns with industry standards for rare disease treatments and reflects the complexity of the therapy.
Who invested in Spruce Biosciences
9 investors across 2 rounds
See all investors in Spruce Biosciences
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Spruce Biosciences
Who invested in Spruce Biosciences?
Spruce Biosciences has 9 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Spruce Biosciences raised?
Spruce Biosciences has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Spruce Biosciences last raise money?
Spruce Biosciences's most recent round on record is a Series B, in Feb 2020.
What does Spruce Biosciences do?
Spruce Biosciences is a biotechnology company.
Where is Spruce Biosciences headquartered?
Spruce Biosciences is headquartered in San Francisco, US.
Which VCs invest in companies like Spruce Biosciences?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Spruce Biosciences's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Spruce Biosciences? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.